USRM
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2022 Q4 | -0.00 | $19,974 | -$43,065 |
| 2022 Q3 | -0.00 | $14,247 | -$64,672 |
| 2022 Q2 | -0.00 | $24,518 | -$133,309 |
| 2022 Q1 | -0.00 | $23,310 | -$63,806 |
| 2021 Q4 | -0.00 | $23,593 | -$216,701 |
| 2021 Q3 | -0.00 | $57,334 | -$206,005 |
| 2021 Q2 | -0.00 | $35,442 | -$317,718 |
| 2021 Q1 | -0.00 | $84,380 | -$317,515 |